vs
亨斯迈（HUN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
亨斯迈的季度营收约是Revvity的1.8倍（$1.4B vs $772.1M），Revvity净利率更高（12.7% vs -7.1%，领先19.8%），Revvity同比增速更快（5.9% vs -6.7%），Revvity自由现金流更多（$161.8M vs $19.0M），过去两年Revvity的营收复合增速更高（9.0% vs -4.0%）
亨斯迈公司是总部位于美国得克萨斯州伍德兰兹的全球化化工巨头，面向消费端与工业客户生产、销售各类化工产品，主营聚氨酯、高性能材料及胶粘剂，客户覆盖宝马、通用电气、雪佛龙、宝洁、联合利华等知名品牌。目前公司在全球25个国家设有60余处生产、研发及运营基地，员工约7000人。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HUN vs RVTY — 直观对比
营收规模更大
HUN
是对方的1.8倍
$772.1M
营收增速更快
RVTY
高出12.5%
-6.7%
净利率更高
RVTY
高出19.8%
-7.1%
自由现金流更多
RVTY
多$142.8M
$19.0M
两年增速更快
RVTY
近两年复合增速
-4.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $772.1M |
| 净利润 | $-96.0M | $98.4M |
| 毛利率 | 12.1% | — |
| 营业利润率 | -4.4% | 14.5% |
| 净利率 | -7.1% | 12.7% |
| 营收同比 | -6.7% | 5.9% |
| 净利润同比 | 31.9% | 3.9% |
| 每股收益（稀释后） | $-0.56 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HUNRVTY
| Q4 25 | $1.4B | $772.1M | ||
| Q3 25 | $1.5B | $698.9M | ||
| Q2 25 | $1.5B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.5B | $729.4M | ||
| Q3 24 | $1.5B | $684.0M | ||
| Q2 24 | $1.6B | $691.7M | ||
| Q1 24 | $1.5B | $649.9M |
净利润HUNRVTY
| Q4 25 | $-96.0M | $98.4M | ||
| Q3 25 | $-25.0M | $46.7M | ||
| Q2 25 | $-158.0M | $53.9M | ||
| Q1 25 | $-5.0M | $42.2M | ||
| Q4 24 | $-141.0M | $94.6M | ||
| Q3 24 | $-33.0M | $94.4M | ||
| Q2 24 | $22.0M | $55.4M | ||
| Q1 24 | $-37.0M | $26.0M |
毛利率HUNRVTY
| Q4 25 | 12.1% | — | ||
| Q3 25 | 14.0% | 53.6% | ||
| Q2 25 | 12.5% | 54.5% | ||
| Q1 25 | 14.3% | 56.5% | ||
| Q4 24 | 12.9% | — | ||
| Q3 24 | 15.2% | 56.3% | ||
| Q2 24 | 15.4% | 55.7% | ||
| Q1 24 | 13.7% | 54.6% |
营业利润率HUNRVTY
| Q4 25 | -4.4% | 14.5% | ||
| Q3 25 | 0.4% | 11.7% | ||
| Q2 25 | -8.2% | 12.6% | ||
| Q1 25 | 3.0% | 10.9% | ||
| Q4 24 | -4.3% | 16.3% | ||
| Q3 24 | 2.7% | 14.3% | ||
| Q2 24 | 2.2% | 12.4% | ||
| Q1 24 | -2.6% | 6.8% |
净利率HUNRVTY
| Q4 25 | -7.1% | 12.7% | ||
| Q3 25 | -1.7% | 6.7% | ||
| Q2 25 | -10.8% | 7.5% | ||
| Q1 25 | -0.4% | 6.4% | ||
| Q4 24 | -9.7% | 13.0% | ||
| Q3 24 | -2.1% | 13.8% | ||
| Q2 24 | 1.4% | 8.0% | ||
| Q1 24 | -2.5% | 4.0% |
每股收益（稀释后）HUNRVTY
| Q4 25 | $-0.56 | $0.86 | ||
| Q3 25 | $-0.14 | $0.40 | ||
| Q2 25 | $-0.92 | $0.46 | ||
| Q1 25 | $-0.03 | $0.35 | ||
| Q4 24 | $-0.82 | $0.77 | ||
| Q3 24 | $-0.19 | $0.77 | ||
| Q2 24 | $0.13 | $0.45 | ||
| Q1 24 | $-0.22 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.0M | $919.9M |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $2.8B | $7.3B |
| 总资产 | $7.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.73× | — |
8季度趋势，按日历期对齐
现金及短期投资HUNRVTY
| Q4 25 | $429.0M | $919.9M | ||
| Q3 25 | $468.0M | $931.4M | ||
| Q2 25 | $399.0M | $991.8M | ||
| Q1 25 | $334.0M | $1.1B | ||
| Q4 24 | $340.0M | $1.2B | ||
| Q3 24 | $330.0M | $1.2B | ||
| Q2 24 | $335.0M | $2.0B | ||
| Q1 24 | $552.0M | $1.7B |
总债务HUNRVTY
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | $2.1B | — |
股东权益HUNRVTY
| Q4 25 | $2.8B | $7.3B | ||
| Q3 25 | $2.8B | $7.4B | ||
| Q2 25 | $2.8B | $7.6B | ||
| Q1 25 | $3.0B | $7.6B | ||
| Q4 24 | $3.0B | $7.7B | ||
| Q3 24 | $3.1B | $7.9B | ||
| Q2 24 | $3.1B | $7.9B | ||
| Q1 24 | $3.2B | $7.8B |
总资产HUNRVTY
| Q4 25 | $7.0B | $12.2B | ||
| Q3 25 | $7.1B | $12.1B | ||
| Q2 25 | $7.1B | $12.4B | ||
| Q1 25 | $7.2B | $12.4B | ||
| Q4 24 | $7.1B | $12.4B | ||
| Q3 24 | $7.3B | $12.8B | ||
| Q2 24 | $7.3B | $13.4B | ||
| Q1 24 | $7.6B | $13.4B |
负债/权益比HUNRVTY
| Q4 25 | 0.73× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.62× | — | ||
| Q3 24 | 0.60× | — | ||
| Q2 24 | 0.62× | — | ||
| Q1 24 | 0.65× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $76.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $19.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 1.4% | 21.0% |
| 资本支出强度资本支出/营收 | 4.2% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $116.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HUNRVTY
| Q4 25 | $76.0M | $182.0M | ||
| Q3 25 | $196.0M | $138.5M | ||
| Q2 25 | $91.0M | $134.3M | ||
| Q1 25 | $-74.0M | $128.2M | ||
| Q4 24 | $153.0M | $174.2M | ||
| Q3 24 | $129.0M | $147.9M | ||
| Q2 24 | $46.0M | $158.6M | ||
| Q1 24 | $-65.0M | $147.6M |
自由现金流HUNRVTY
| Q4 25 | $19.0M | $161.8M | ||
| Q3 25 | $153.0M | $120.0M | ||
| Q2 25 | $54.0M | $115.5M | ||
| Q1 25 | $-110.0M | $112.2M | ||
| Q4 24 | $102.0M | $149.8M | ||
| Q3 24 | $88.0M | $125.6M | ||
| Q2 24 | $-4.0M | $136.6M | ||
| Q1 24 | $-107.0M | $129.7M |
自由现金流率HUNRVTY
| Q4 25 | 1.4% | 21.0% | ||
| Q3 25 | 10.5% | 17.2% | ||
| Q2 25 | 3.7% | 16.0% | ||
| Q1 25 | -7.8% | 16.9% | ||
| Q4 24 | 7.0% | 20.5% | ||
| Q3 24 | 5.7% | 18.4% | ||
| Q2 24 | -0.3% | 19.7% | ||
| Q1 24 | -7.3% | 20.0% |
资本支出强度HUNRVTY
| Q4 25 | 4.2% | 2.6% | ||
| Q3 25 | 2.9% | 2.6% | ||
| Q2 25 | 2.5% | 2.6% | ||
| Q1 25 | 2.6% | 2.4% | ||
| Q4 24 | 3.5% | 3.4% | ||
| Q3 24 | 2.7% | 3.3% | ||
| Q2 24 | 3.2% | 3.2% | ||
| Q1 24 | 2.9% | 2.7% |
现金转化率HUNRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 2.09× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HUN
| Diversified | $897.0M | 66% |
| Specialty | $231.0M | 17% |
| Performance Products | $113.0M | 8% |
| Advanced Materials | $61.0M | 5% |
| Related Party Customers | $19.0M | 1% |
| Other | $12.0M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
